VascuStim is in the business of developing treatments utilizing the innovative advancements in bioelectric stimulation controlled protein expression, stem cell homing, proliferation and differentiation combined with stem cel based mixed compositions such as amniotic fluid which has over 240 known growth factors critical and important to healthy tissue and organ development and repair. We committed to gathering data in well controlled studies with patient safety always established first and foremost. Our stem cell based compositions are procured and handled by an FDA HCT/P certified lab. The company prides itself on its state-of-the-art technology and its ability to provide products of the highest standards in the industry. Our amniotic fluid and membranes are processed from donated human tissue from full term deliveries and are regulated as a human cell, tissue, or cellular or tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act.
CAUTION: Investigational device. Limited by Federal (or United States) law to investigational use.
Bioelectric + light therapy stimulation and amniotic fluid combination designed to treat:
VascuStim’s mission is to harness the power of precise bioelectric signaling.
71% Electrical Stimulated Ulcers Healed only
39% in Placebo Control Group Healed
1 Year Out Diabetic Foot Ulcers Treated with Best Standard Current Therapies
- 44.5% healed
- 17.4% AMPUTATED!
- 38.1% NOT HEALED!
5 years out data is much worse!
- Outcomes for people with a clinically infected diabetic foot ulcer are poorer than previously thought; in the first year after presentation with an infected ulcer, 15.1% of our participants had died and 17.4% underwent at least partial lower extremity amputation.
- Healing incidence within 1 year was 44.5% (95% CI 38.9 to 50.1). Three key factors served as the best independent predictors of healing: PEDIS (perfusion, extent, depth, infection, sensation) perfusion grade; the absence of multiple foot ulcers; and shorter ulcer duration.